Drugs that contain Buprenorphine Hydrochloride; Naloxone Hydrochloride
1. Drug name - BUNAVAIL
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8147866 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(4 years from now) | |
| US9655843 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(4 years from now) | |
| US8703177 | BDSI | Abuse-resistant mucoadhesive devices for delivery of buprenorphine |
Aug, 2032
(9 years from now) | |
| US9522188 | BDSI | Abuse resistant transmucosal drug delivery device |
Apr, 2035
(12 years from now) | |
Treatment: Maintenance treatment of opioid dependence; Treatment of opioid dependence
Dosage: FILM;BUCCAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 2.1MG BASE;EQ 0.3MG BASE | FILM;BUCCAL | Discontinued |
| EQ 4.2MG BASE;EQ 0.7MG BASE | FILM;BUCCAL | Discontinued |
| EQ 6.3MG BASE;EQ 1MG BASE | FILM;BUCCAL | Discontinued |
2. Drug name - SUBOXONE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10285910 | INDIVIOR INC | Sublingual and buccal film compositions |
Oct, 2022
(5 days from now) | |
| US8017150 | INDIVIOR INC | Polyethylene oxide-based films and drug delivery systems made therefrom |
Feb, 2023
(4 months from now) | |
| US8603514 | INDIVIOR INC | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Apr, 2024
(1 year, 5 months from now) | |
| US9687454 | INDIVIOR INC | Sublingual and buccal film compositions |
Aug, 2029
(6 years from now) | |
| US11135216 | INDIVIOR INC | Sublingual and buccal film compositions |
Aug, 2029
(6 years from now) | |
| US8475832 | INDIVIOR INC | Sublingual and buccal film compositions |
Mar, 2030
(7 years from now) | |
Treatment: Treatment of opioid dependence/sublingual or buccal application; Treating opioid use disorder; This drug is administered by sublingual route to humans for maintenance treatment of opioid dependence
Dosage: FILM;BUCCAL, SUBLINGUAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 2MG BASE;EQ 0.5MG BASE | FILM;BUCCAL, SUBLINGUAL | Prescription |
| EQ 4MG BASE;EQ 1MG BASE | FILM;BUCCAL, SUBLINGUAL | Prescription |
| EQ 8MG BASE;EQ 2MG BASE | FILM;BUCCAL, SUBLINGUAL | Prescription |
| EQ 12MG BASE;EQ 3MG BASE | FILM;BUCCAL, SUBLINGUAL | Prescription |
3. Drug name - ZUBSOLV
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8658198 | OREXO US INC | Non-abusable pharmaceutical composition comprising opioids |
Dec, 2027
(5 years from now) | |
| US8470361 | OREXO US INC | Non-abusable pharmaceutical composition comprising opioids |
May, 2030
(7 years from now) | |
| US11020387 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(9 years from now) | |
| US11020388 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(9 years from now) | |
| US8940330 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(9 years from now) | |
| US9439900 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(9 years from now) | |
| US9259421 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(9 years from now) | |
| US10874661 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(9 years from now) | |
| US10946010 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(9 years from now) | |
Treatment: Sublingual or buccal administration of a pharmaceutical composition comprising buprenorphine and naloxone; Sublingual administration of a pharmaceutical composition comprising buprenorphine and naloxone; Use of zubsolv for treatment of opioid dependence
Dosage: TABLET;SUBLINGUAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 0.7MG BASE;EQ 0.18MG BASE | TABLET;SUBLINGUAL | Prescription |
| EQ 1.4MG BASE;EQ 0.36MG BASE | TABLET;SUBLINGUAL | Prescription |
| EQ 2.9MG BASE;EQ 0.71MG BASE | TABLET;SUBLINGUAL | Prescription |
| EQ 5.7MG BASE;EQ 1.4MG BASE | TABLET;SUBLINGUAL | Prescription |
| EQ 8.6MG BASE;EQ 2.1MG BASE | TABLET;SUBLINGUAL | Prescription |
| EQ 11.4MG BASE;EQ 2.9MG BASE | TABLET;SUBLINGUAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.